Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost-Effectiveness Evaluation of Aspirin in Primary Prevention of Myocardial Infarction Amongst Males With Average Cardiovascular Risk in Iran Publisher



Amirsadri M1 ; Sedighi MJ1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Dept. of Clinical Pharmacy and Pharmacy Practice and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Research in Pharmaceutical Sciences Published:2017


Abstract

Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectiveness of the use of aspirin in the primary prevention of MI among Iranian men with average cardiovascular disease (CVD) risk, using Markov modeling technique. The incremental cost-effectiveness ratios (ICERs) estimated to be 864 USA dollars (USD) per quality-Adjusted life years (QALY) gained and 782 USD per life years gained (LYG) for each patient in the base-case scenario (public tariffs and no discounting). This research proves costeffectiveness of the use of aspirin in the primary prevention of MI in targeted population, since the assessed ICERs are quite under the recommended threshold by WHO which is one gross domestic product (GDP) per capita ($5315.1 for Iran in 2015).
Related Docs
View other Related Docs
1. Cost-Effectiveness and Cost-Utility Analysis of Otc Use of Simvastatin 10 Mg for the Primary Prevention of Myocardial Infarction in Iranian Men, DARU, Journal of Pharmaceutical Sciences (2015)
2. Model-Based Cost-Effectiveness Analysis of Atorvastatin Drugs for Prevention of Cardiovascular Diseases in Iran, International Journal of Preventive Medicine (2020)
3. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
4. Total Cardiovascular Risk Approach to Improve Efficiency of Cardiovascular Prevention in Resource Constrain Settings, Journal of Clinical Epidemiology (2011)
5. The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients With Cardiovascular Disease, a Systematic Review, International Journal of Preventive Medicine (2021)
6. A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial; [کارآزمایی بالینی تصادفی Persianpolypill شدهی مروری بر درمان ترکیبی با دوز ثابت برای پیشگیری ثانویه از حوادث نامطلوب قلبی- عروقی و نتایج اولیهی], Journal of Isfahan Medical School (2024)
7. The Pattern of In-Hospital Mortality of Myocardial Infarction and Associated Factors in Iran: A National Study, Journal of Isfahan Medical School (2015)
8. The Cost-Effectiveness and Cost-Utility Analysis of the Use of Enoxaparin Compared With Heparin for Venous Thromboembolism Prophylaxis in Medical Inpatients in Iran, DARU, Journal of Pharmaceutical Sciences (2019)
Experts (# of related papers)
View all Related Experts
Nizal Sarrafzadegan (8)
Masoumeh Sadeghi (8)
Other Related Docs
9. Aspirin Resistance Status As Determined by Urinary Thromboxane B 2 (Txb2) Level in Patients With Ischemic Heart Disease and Its Relationship With Severity of Coronary Artery Disease, Journal of Isfahan Medical School (2011)
10. A Study on the Effect of Aspirin on Clinical Symptoms, Laboratory Indices, and Outcomes in Patients With Covid-19, Journal of Nephropharmacology (2023)
11. Cost-Effectiveness of Hypertension Therapy Based on 2020 International Society of Hypertension Guidelines in Ethiopia From a Societal Perspective, PLoS ONE (2022)
12. Availability and Affordability of Medicines and Cardiovascular Outcomes in 21 High-Income, Middle-Income and Low-Income Countries, BMJ Global Health (2020)
13. Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting, Global Heart (2024)
14. Risk of Fatal and Nonfatal Coronary Heart Disease and Stroke Events Among Adult Patients With Hypertension: Basic Markov Model Inputs for Evaluating Cost-Effectiveness of Hypertension Treatment: Systematic Review of Cohort Studies, Journal of Pharmaceutical Health Services Research (2021)
15. Covid-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran, Vaccines (2022)
16. Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases (Polyiran): A Pragmatic, Cluster-Randomised Trial, The Lancet (2019)
17. Cardiovascular and Bleeding Events of Ticagrelor Monotherapy After Short-Term Dual Antiplatelet Therapy (Dapt) in Diabetics and Non-Diabetics Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis, ARYA Atherosclerosis (2023)
18. Coronary Bypass Surgery Versus Percutaneous Coronary Intervention: Cost-Effectiveness in Iran: A Study in Patients With Multivessel Coronary Artery Disease, International Journal of Technology Assessment in Health Care (2014)
19. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, a Randomized Clinical Trial, Current Problems in Cardiology (2022)
20. The Use and the Cost of Outpatient Diagnostic Procedures for Cardiovascular Diseases in Isfahan Province: A Utilization Study, Journal of Education and Health Promotion (2022)
21. Polypill for the Prevention of Cardiovascular Disease (Polyiran): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial, European Journal of Preventive Cardiology (2015)
22. Availability and Affordability of Cardiovascular Disease Medicines and Their Effect on Use in High-Income, Middle-Income, and Low-Income Countries: An Analysis of the Pure Study Data, The Lancet (2016)
23. The Prevalence of the Risk Factors Associated With Cardiovascular Diseases Among Iranian Adults: Findings of a Cross‑Sectional Study, Journal of Education and Health Promotion (2024)
24. Background and Design of a 5-Year St Elevation Myocardial Infarction Cohort in Isfahan, Iran: Semi-Ci Study, ARYA Atherosclerosis (2022)
25. Integrated Care Pathway for Acute Coronary Syndromes: Does It Help?, Journal of Integrated Care Pathways (2008)
26. Cost-Effectiveness and Cost-Utility Analysis of Type-2 Diabetes Screening in Pharmacies in Iran, Research in Pharmaceutical Sciences (2023)